MedTrace Logo

A Study of Patient Management in HIV-1 Infected Patients Found to Have the Genetic Marker HLA-B*5701

NCT00435838 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2008-10-15

No results posted yet for this study

Summary

This is a retrospective observational study which follows on from CNA106030 (a study evaluating whether prospective genetic screening for HLA-B\*5701 can reduce the incidence of hypersensitivity reactions to abacavir). This study aims to collect data on approximately 35 subjects who withdrew from CNA106030 when found to be HLA-B\*5701 positive. HIV disease management and adverse event data in these subjects, where the risk/benefit ratio of treatment with abacavir may alter subsequent prescribing, will be collected

Conditions

  • HIV Infection

Interventions

DRUG

No Intervention -- Observational study

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials, PhD · GlaxoSmithKline

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31

Countries

  • Austria
  • Belgium
  • Italy
  • Russia
  • Slovenia
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00435838 on ClinicalTrials.gov